Cranberry for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Cranberry for Health & Longevity

Created on 09/23/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Cranberry, a tart berry taken as juice, dried fruit or extract, is used to help prevent bladder infections. The best-supported benefit is fewer repeat infections in infection-prone women and children and after medical procedures; it has not been shown to treat an active infection. Evidence beyond the bladder is thinner. Risks are modest: added sugar, possible kidney-stone risk at large intakes and an unsettled interaction with the blood thinner warfarin. (Full Review)

Protocol

PAC-standardized extract
36 mg PACs daily
PACs: tannin-like plant compounds; or 72 mg; measured by BL-DMAC method (a standardized dye assay); higher doses usually split into morning and evening
Juice
240 mL daily
27% cranberry juice beverage; 2 × 240 mL low-calorie juice for heart and metabolic markers
Time of day
Evening
Covers the overnight period when urine sits in the bladder; twice-daily dosing maintains urinary anti-adhesion (blocking bacteria from sticking to the bladder lining) across 24 hours
Time to effect
Fewer urinary tract infections (UTIs)
3–6 months
Urinary anti-adhesion appears within hours
Vascular effects
2 hours and 1 month
Blood vessel function
Memory changes
12 weeks
Visual episodic memory (recall of seen events) in adults aged 50–80

Benefits

Contraindications
  • People with prior calcium oxalate stones or 24-hour urinary oxalate above 40 mg/day (concentrated extracts)
  • Warfarin users with unstable control (time in therapeutic INR range below 60%) unless INR is closely monitored
  • People with aspirin (salicylate) allergy or aspirin-triggered asthma
  • People with diabetes and HbA1c (3-month average blood sugar) above 7% (sweetened products)
  • People with signs of kidney infection (fever above 38 °C, flank pain) relying on cranberry instead of treatment
    •
Key Interactions
  • Vitamin K antagonist anticoagulants (blood thinners that block vitamin K recycling: warfarin, acenocoumarol, phenprocoumon): Caution; possible raised INR (a clotting test) and bleeding
  • Direct oral anticoagulants (newer blood thinners) and antiplatelet drugs (which stop platelets clumping) (apixaban, rivaroxaban, clopidogrel): Monitor; no documented interaction, but theoretical additive bleeding
  • Over-the-counter salicylates and NSAIDs (non-steroidal anti-inflammatory drugs, common pain relievers: aspirin, ibuprofen, naproxen): Caution in warfarin users; additive bleeding tendency
  • Supplements with blood-thinning effects (fish oil, ginkgo, garlic, vitamin E): Caution in warfarin users; additive bleeding tendency
  • High-dose vitamin C (above 1 g daily): Caution in stone formers; additive urinary oxalate
  • High-oxalate diet (spinach, rhubarb, almonds): Caution in stone formers; additive oxalate load
  • Drugs cleared by CYP2C9, CYP1A2 or CYP3A4 (tizanidine, midazolam, statins such as atorvastatin, which lower cholesterol): Low concern; no action identified
  • Preventive antibiotics (nitrofurantoin, trimethoprim): No harmful interaction
  • Supplements with additive anti-infection effects (D-mannose, Lactobacillus probiotics): Additive, non-harmful effect on UTI prevention
    •

Risk & Side Effects

  • High:
  • Medium: Blood sugar spikes from sweetened products
    •
  • Low: Stronger warfarin effect and bleeding; higher calcium oxalate kidney-stone risk; gastrointestinal upset
    •
  • Speculative: Salicylate exposure in aspirin-sensitive people; delayed treatment of an active infection
    •

Monitoring

Marker Target Why
Symptomatic UTI count 0 per 6 months; at least 30% fewer than own baseline Main efficacy outcome
Urinalysis (leukocyte esterase, nitrite) Negative Detects infection
INR (warfarin users only) 2.0–3.0, or the individual's target range Detects a strengthened warfarin effect
24-hour urinary oxalate Below 25 mg/day Stone risk
24-hour urinary calcium Below 200 mg/day Stone risk
Fasting glucose 75–90 mg/dL Metabolic effect and sugar load
HbA1c Below 5.4% Long-term glucose
Triglycerides Below 100 mg/dL Metabolic effect
HDL cholesterol Above 60 mg/dL Metabolic effect
High-sensitivity CRP Below 1.0 mg/L Inflammation
Blood pressure Below 120/80 mmHg Vascular effect

Cadence: Baseline before starting; INR at 1 and 4 weeks after starting or changing intake (warfarin users); monthly UTI diary with urine culture for any suspected infection; repeat 24-hour urine at 3 months (stone formers); metabolic labs at 3 months, then every 6–12 months

Qualitative Assessment

  • Urinary comfort, urgency and frequency
  • Gastrointestinal tolerance (abdominal discomfort, reflux, stool changes)
  • Urinary flow and night-time urination in men
  • Memory and mental clarity
  • Unusual bruising or bleeding in warfarin users
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.